-
Product Insights
Heterozygous familial hypercholesterolemia (heFH) - Drugs In Development, 2024
Empower your strategies with our Heterozygous familial hypercholesterolemia (heFH) – Drugs In Development, 2024 report and make more profitable business decisions. Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused by getting a mutation of the FH gene from an affected parent. Symptoms include xanthesmas, corneal arcus, aortic rupture, and peripheral vascular disease. Risk factors include age, sex, smoking, and hypertension, or associated lipid abnormalities such as low HDL-C levels, high TG levels, or type III dyslipoproteinemia. The Heterozygous familial hypercholesterolemia...
-
Product Insights
Organic Acidemia - Drugs In Development, 2024
Empower your strategies with our Organic Acidemia – Drugs In Development, 2024 report and make more profitable business decisions. Organic acidemia or organic acidurias are a group of inherited metabolic disorders characterized by the accumulation of abnormal organic acid metabolites in the body fluids and tissues. They are caused by a deficiency in an enzyme necessary to break down amino acids, thus causing increased organic acids in body fluids that are then excreted in urine. Vomiting, poor feeding, failure to thrive,...
-
Product Insights
Proliferative Diabetic Retinopathy (PDR) - Drugs In Development, 2024
Empower your strategies with our Proliferative Diabetic Retinopathy (PDR) – Drugs In Development, 2024 report and make more profitable business decisions. Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. PDR occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue, causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy, and tobacco use. Symptoms include spots or dark...
-
Product Insights
Primary Systemic Amyloidosis - Drugs In Development, 2024
Empower your strategies with our Primary Systemic Amyloidosis – Drugs In Development, 2024 report and make more profitable business decisions. Primary systemic amyloidosis is a rare disorder in which abnormal proteins build up in tissues and organs. Clumps of the abnormal proteins are called amyloid deposits. It is plasma-cell dyscrasia characterized by an autonomous proliferation of plasma cells with an overproduction of a monoclonal Ig protein. The final pathway in the development of amyloidosis is the production of amyloid fibrils in...
-
Product Insights
Amyloid Cardiomyopathy - Drugs In Development, 2024
Empower your strategies with our Amyloid Cardiomyopathy – Drugs In Development, 2024 report and make more profitable business decisions. Amyloid cardiomyopathy (stiff heart syndrome) is a condition resulting in the death of part of the myocardium (heart muscle). It is associated with the systemic production and release of many amyloidogenic proteins, especially immunoglobulin light chain or transthyretin (TTR). The Amyloid Cardiomyopathy drugs in development market research report provide comprehensive information on the therapeutics under development for Amyloid Cardiomyopathy, complete with analysis...
-
Product Insights
Hyperinsulinemia - Drugs In Development, 2024
Empower your strategies with our Hyperinsulinemia – Drugs In Development, 2024 report and make more profitable business decisions. Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue, and frequent hunger. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes, and hypertension. Treatment includes insulin secretion inhibiting agents, diet,...
-
Product Insights
Non-Proliferative Diabetic Retinopathy (NPDR) - Drugs In Development, 2024
Empower your strategies with our Non-Proliferative Diabetic Retinopathy (NPDR) – Drugs In Development, 2024 report and make more profitable business decisions. Non-proliferative diabetic retinopathy (NPDR) is the early stage of the disease in which symptoms will be mild or nonexistent. In NPDR, the blood vessels in the retina are weakened. Tiny bulges in the blood vessels, called microaneurysms, may leak fluid into the retina. This leakage may lead to swelling of the macula. The Non-Proliferative Diabetic Retinopathy (NPDR) drugs in development...
-
Product Insights
Insulin Resistance - Drugs In Development, 2024
Empower your strategies with our Insulin Resistance – Drugs In Development, 2024 report and make more profitable business decisions. Insulin resistance (IR) is a condition in which the body's cells become resistant to the effects of insulin. This occurs when insulin levels are sufficiently high over a prolonged period of time, causing the body’s own sensitivity to the hormone to be reduced. Symptoms include lethargy, hunger, difficulty concentrating, and high blood pressure. Predisposing factors include obesity and hypertension. The Insulin Resistance...
-
Product Insights
Methylmalonic Acidemia - Drugs In Development, 2024
Empower your strategies with our Methylmalonic Acidemia – Drugs In Development, 2024 report and make more profitable business decisions. Methylmalonic Acidemia is an inborn or inherited metabolic disease where the levels of MMA (methylmalonic acid) are elevated in blood and urine. Deficiency in MMA Defect in conversion of methylmalonyl-coenzyme A (CoA) to succinyl-CoA causes accumulation of methylmalonyl-CoA and other potentially toxic compounds. It can be mild to severe appearing in early stages of life or in later stages. Seizures, encephalopathy and...
-
Product Insights
Mixed Dyslipidemia - Drugs In Development, 2024
Empower your strategies with our Mixed Dyslipidemia – Drugs In Development, 2024 report and make more profitable business decisions. Dyslipidemia is a condition where the lipid levels in blood are either low or high. While in mixed dyslipidemia the levels of LDL (low density lipoprotein) and TG (triglycerides) are elevated, and HDL (high density lipoprotein) is low. This occurs when there is an overproduction of very low-density lipoprotein (VLDL) leading to an increase in LDL and TG. People with mixed dyslipidemia...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.